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Abstract
Background: HIV-infected persons suffering from tuberculosis experience high mortality. No programmatic studies from
India have documented the delivery of mortality-reducing interventions, such as cotrimoxazole prophylactic treatment
(CPT) and antiretroviral treatment (ART). To guide TB-HIV policy in India we studied the effectiveness of delivering CPT and
ART to HIV-infected persons treated for tuberculosis in three districts in Andhra Pradesh, India, and evaluated factors
associated with death.
Methods and Findings: We retrospectively abstracted data for all HIV-infected tuberculosis patients diagnosed from March
2007 through August 2007 using standard treatment outcome definitions. 734 HIV-infected tuberculosis patients were
identified; 493 (67%) were males and 569 (80%) were between the ages of 24–44 years. 710 (97%) initiated CPT, and 351
(50%) collected .60% of their monthly cotrimoxazole pouches provided throughout TB treatment. Access to ART was
documented in 380 (51%) patients. Overall 130 (17%) patients died during TB treatment. Patients receiving ART were less
likely to die (adjusted hazard ratio [HR] 0.4, 95% confidence interval [CI] 0.3–0.6), while males and those with pulmonary TB
were more likely to die (HR 1.7, 95% CI 1.1–2.7, and HR 1.9, 95% CI 1.1–3.2 respectively).
Conclusions: Among HIV-infected TB patients in India death was common despite the availability of free cotrimoxazole
locally and ART from referral centres. Death was strongly associated with the absence of ART during TB treatment. To
minimize death, programmes should promote high levels of ART uptake and closely monitor progress in implementation.
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Introduction
India has the world’s highest burden of tuberculosis (TB) with
1.9 million estimated incident cases per year. It also ranks among
the world’s highest HIV burden with an estimated 2.3 million
persons living with HIV/AIDS [1,2]. Tuberculosis is much more
likely to be a fatal disease among HIV-infected persons than
persons without HIV infection [3,4,5]. The World Health
Organization (WHO) guidelines for the management of HIV-
infected persons with tuberculosis recommend the provision of
cotrimoxazole prophylactic treatment (CPT) and, if indicated,
antiretroviral treatment (ART) [6].
Cotrimoxazole is a broad-spectrum antimicrobial agent that is
recommended as primary prevention against opportunistic
infections in HIV-infected persons [7]. At the dose of sulfameth-
oxazole 800 mg/trimethoprim 160 mg daily, cotrimoxazole has
been demonstrated to be effective at reducing mortality due to
Pneumocystis pneumonia, toxoplasmosis, and other bacterial
opportunistic infections [8,9,10]. In randomized studies, cotrimox-
azole has reduced mortality in HIV-infected adults newly
diagnosed with tuberculosis; however, data from programmes in
resource-limited countries are scarce [11,12,13,14]. In India,
primary prevention with cotrimoxazole has been recommended by
the National AIDS Control Programme (NACP) for all HIV-
infected patients with WHO Clinical Stage III and IV or those in
Stage II and with CD4 counts of ,200 [15]. CPT prescription and
delivery, however, has previously been left to the discretion of
individual providers and has not been available at primary health
centres where patients routinely access care.
Antiretroviral treatment has been convincingly associated with
improved treatment outcomes and reduced mortality [9,16,17,18].
India has made free antiretroviral treatment widely available
nationwide through a growing treatment network that, as of June
2008, has initiated 134,927 persons on ART at 157 ART centres
[19]. HIV-infected persons are eligible for ART after counseling,
clinical examination, and if immunologic criteria are met; for those
with tuberculosis, CD4 cell count ,350/ml indicates ART
eligibility [20]. No data regarding the effectiveness of referral to
the ART centre network has been reported, and systematic referral
of HIV-infected TB patients for ART was previously not practiced.
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Revised National TB Control Programme (RNTCP) and NACP
implemented a demonstration project in three districts in the state
of Andhra Pradesh. The project’s goal was to deliver the WHO-
recommended interventions of CPT and ART (as per national
guidelines) to all known HIV-infected TB patients. We retrospec-
tively evaluated the efficiency of decentralized CPT delivery from
primary health centres, assessed the effectiveness of referral links to
ART centres, and studied factors associated with mortality among




Three districts in the southern Indian state of Andhra
Pradesh—Ananthapur, Vizianagaram, and Vishakapatnam (com-
bined 2001 population 9.7 million)—were intentionally selected to
implement these TB-HIV activities on the basis of high HIV
prevalence among antenatal clinic attendees during NACP
surveillance from 2003–2006. In the three districts there are a
total of 154 primary health care facilities which provide general
health services including TB diagnostic and treatment services. At
the time of implementation of these interventions, there were 47
HIV counseling and testing centres and 3 ART centres for free
HIV diagnosis and treatment (2 ART centres in Ananthapur, 1 in
Vishakapatnam and none in Vizianagaram). HIV treatment and
care, including ART, was available free of cost to patients at these
ART centres. Patients from Vizianagaram district were able to
access ART services in the adjacent district of Vishakapatnam.
Interventions
TB diagnosis under RNTCP is based on initial smear
microscopy, but allows for the diagnosis of smear-negative and
extrapulmonary TB as well. Pulmonary TB diagnosis is based on a
standard diagnostic algorithm [21]. Patients identified as TB
suspects are subject to sputum microscopy; those with sputum
microscopy results positive for acid-fast bacilli are declared TB
cases, and patients with negative sputum results are offered a course
of antibiotics. Patients who remain symptomatic after antibiotics are
offered repeat sputum examination and, if still sputum-negative, a
chest radiograph. On the basis of negative sputum results and
clinicalandradiographicexamination,anycliniciancandeclareany
patient to be a case of smear-negative pulmonary TB. Extrapul-
monary TB is generally left to the provider to declare diagnosis on
clinical and pathological examination, but standard algorithms are
provided for lymph node and pleural tuberculosis. All TB patients
received free, standardized anti-TB treatment as per national
guidelines [21]. For new patients RNTCP uses an intensive phase
regimen of isoniazid, pyrazinamide, rifampicin, and ethambutol
dosed thrice-weekly for 2 months under direct observation, and a
continuation phase regimen of isoniazid and rifampicin dosed
thrice-weeklyfor4monthswith directobservation ofatleastthe first
dose per week. For re-treatment patients, RNTCP uses an intensive
phase of isoniazid, pyrazinamide, rifampicin, and ethambutol dosed
thrice weekly for 3 months (along with streptomycin for the first 2
months), and a continuation phase regimen of isoniazid, rifampicin,
and ethambutol dosed thrice-weekly for 6 months. In any regimen,
those smear-positive patients who remain smear-positive after the
normal intensive phase treatment have their intensive phase
extended by one month. Treatment duration is determined by the
number of doses, and the durations above assume that all doses are
taken; missed doses lead to a longer total duration of treatment.
Providers were instructed to immediately refer all TB patients
with any HIV risk factors to the nearest HIV counseling and
testing centre, as per the prevailing national guidelines at the time.
HIV test results were communicated to the referring provider
either directly by the patient or via direct communication from
HIV counselor to the referring provider (with patient assent). An
initial 1-month supply of CPT, at the dose of sulfamethoxazole
800 mg/trimethoprim 160 mg daily (one ‘‘double strength’’
cotrimoxazole tablet) was provided to the HIV-infected TB
patients from their respective primary health centres, and 1-
month refills made available for the duration of their TB treatment
at no cost. While being providing CPT, patients were counseled on
the benefits of CPT, possible side effects, and the importance of
adherence. In an attempt to address concerns about patient
privacy, CPT was available at primary health centres only from
health care workers, and not through community DOT providers.
At the start of the intervention, CPT became available for all HIV-
infected TB patients at the same time, regardless of whether a
patient was newly diagnosed with TB or already on TB treatment
for several months.
Providers were asked to refer HIV-infected TB patients to the
nearest ART centre as soon as possible, but at least 2 weeks after
the initiation of anti-TB treatment (to address the infection control
concerns). Patients were asked to continue CPT from ART centres
after their TB treatment was completed, or earlier if ART were
initiated during TB treatment.
The RNTCP individual patient TB treatment cards were
modified to enable recording of HIV status, CPT initiation, CPT
adherence, and ART information. Trainings were conducted for
all district medical officers, programme staff of NACP and
RNTCP, and pharmacists at peripheral health facilities. Standard
forms were developed to facilitate referrals and feedback on results
of HIV testing and ART evaluations. TB programme staff
maintained a separate register of HIV-infected TB patients to
facilitate supervision and monitoring.
Definitions
Standard definitions were used to categorize patients according
to TB type and treatment outcomes [21]. New cases were defined
as those TB patients who had less than 1-month of previous anti-
TB treatment. Treatment success was defined as having a
treatment outcome of cured or completed treatment as docu-
mented on the TB treatment card. Any death that occurred during
TB treatment was classified as ‘‘death during treatment’’. If the
date of ART or CPT treatment initiation was more than 1 week
before TB treatment initiation, that person was said to be on ART
or CPT prior to TB treatment. Patients who initiated ART at any
time before TB treatment was completed were classified as having
received ART during TB treatment.
Data collection and analysis
We retrospectively abstracted data from programme records for
all HIV-infected TB patients notified to the RNTCP between 1
March and 31 August 2007. Treatment cards were collected from
all health facilities and data double entered with Microsoft Excel.
At the end of 6 months RNTCP and NACP conducted field visits
to 30 health service delivery sites in the three districts, and
conducted unstructured interviews with 100 randomly selected
HIV positive TB patients to identify gaps in the delivery of
intervention services.
We compared HIV-infected TB patients who died during TB
treatment with those who did not die. Risk factors for death
analyzed included age, sex, district of residence, type of TB, CPT
use, CPT adherence, and ART provision. To assess CPT
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we expressed the number of monthly CPT dose pouches picked
up—as recorded on TB treatment cards—as a proportion of the
number of months which an HIV-infected TB patient was alive
and on treatment (rounded down to the nearest month). Data on
CD4 cell counts were not available in routine records.
For bivariate analysis, we compared proportions using chi-square,
and for continuous variables we compared medians using the
Wilcoxin Rank-Sum test. The survival distribution of the overall
cohort was estimated using the Kaplan-Meier method, and
subgroups were compared using the Cox-Mantel (log-rank) test. P-
values throughout were 2-sided and we used a 0.05 significance level.
For multivariate analysis we calculated hazard ratios for factors
associated with death using a Cox proportional-hazards model.
The dependent variable was the number of days. Treatment
outcomes other than death were censored after the last day of TB
treatment recorded. We pre-selected variables for inclusion in the
multivariable model based on prior information from studies from
other settings on risk factors for mortality in HIV-infected TB
patients [9,11,17,18,22]. The analysis was conducted using
EpiData 2.0 (EpiData Association, Odense Denmark) and SPSS
14.0 (SPSS Inc., Chicago, USA).
Ethical issues
This retrospective analysis was conducted after review and
approval by the National AIDS Control Programme and the
Central TB Division, Directorate General of Health Services,
Ministry of Health and Family Welfare, Government of India.
The activity was determined to be programme evaluation of the
implementation of internationally-recommended interventions.
Electronic databases created for this analysis were stripped of
personal health identifiers and maintained securely.
Results
Among the 7,752 patients registered in the three districts from
March 1 2007 to August 31 2007, 734 (9.5%) were identified as
HIV-infected. The proportion of registered patients reported to be
HIV-infected varied by district; 322 (9.9%) out of the 3,239 of TB
patients registered from Ananthapur were HIV-infected, as were
317 (11.6%) out of the 2,725 from Vishakapatnam and 95 (5.3%)
out of the 1,788 from Vizianagaram. Characteristics of these 734
HIV-infected TB patients are shown in Table 1. Of these, 493
(67%) were male and the median age was 34 years (range 8–89
years); 80% were between the ages of 25 and 46 years.
Access to CPT
710 (97%) of the 734 known HIV-infected TB patients were
initiated on CPT during the evaluation period; 22 (3%) of patients
were already taking CPT before the start of TB treatment from the
ART centre, and no record of CPT initiation was found for two
patients. Nearly half (323, 44%) received prophylaxis within 1
week of starting TB treatment (Table 2). The exact date of CPT
initiation was not available for 26% of patients, as field staff
commonly only recorded the month of initiation. Overall 351
(48%) collected $60% of the number of monthly cotrimoxazole
pouches provided. Anecdotally, we observed that the on-site
availability of CPT at primary health centers appeared to motivate
providers assess the HIV status of TB patients.
Access to ART
Among the 734 HIV-infected TB patients, 133 (18%) were
documented as already on ART at the time of TB treatment
initiation. Of the 601 HIV-infected TB patients not on ART at the
time of TB treatment initiation, 559 (93%) were documented to
have been referred to ART centres. Of the 559 referrals to ART
centre, 324 (61%) were documented to be subsequently pre-
registered at ART centres. Of the 324, 247 (76%) were initiated on
ART by the end of TB treatment. In total, 380 of 734 (52%) had
access to ART during TB treatment.
TB treatment outcomes
Treatment outcomes were available for all 734 HIV-infected TB
patients (Table 3). Treatment success was reported in 536 (73%)
patients; treatment success was highest among new-extrapulmonary
patients (89%), and was lowest among re-treatment patients (51%).
Treatment default was more common among re-treatment patients
(16%) or new smear-negative TB patients (11%), compared to new
smear-positive TB patients (4.3%) (p,0.01 for each comparison).
The combined treatment success rates in this group of HIV patients
was lower than the overall treatment success rate in the three
districts (84%) during the same time period.
Risk factors for death during TB treatment
Overall 130 (18%) HIV-infected TB patients died during TB
treatment. Bivariate risk factors for death are shown in Table 4.
HIV-infected female patient had a lower risk of death than males
Table 1. Characteristics of HIV-infected TB patients, Andhra
Pradesh, India, 2007 (N=734).
Characteristic Subcategory N (%)
District of Residence Ananthapur 322 (43.8)
Vishakapatnam 317 (43.2)
Vizianagaram 95 (13.0)
Sex Male 493 (67.2)
Female 220 (30.0)
Not available 21 (2.8)
Previous TB treatment Yes 99 (13.5)
No 635 (86.5)
Type of TB Pulmonary 551 (75.1)
Extrapulmonary 183 (24.9)
TB Classification New smear-positive pulmonary 277 (37.7)
New smear-negative pulmonary 190 (25.9)
New extrapulmonary 168 (22.9)
Re-treatment 99 (13.5)
Age Group ,15 years 1 (0.1)
15–24 years 50 (6.8)
25–34 years 318 (43.3)
35–44 years 251 (34.2)
45–54 years 84 (11.4)
.55 years 27 (3.7)
Not available 3 (0.4)








Abbreviations: TB–Tuberculosis; ART–antiretroviral treatment.
doi:10.1371/journal.pone.0005999.t001
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patients were more likely to die than new patients (RR 1.92, 95%
CI 1.36–2.73). Death occurred in 43 of 380 (11.3%) patients
exposed to ART during TB treatment, compared with 87 of 354
patients (24.6%) without ART (RR 0.46, 95% CI 0.33–0.64).
Kaplan Meier plots showed that divergence in survival between
those with and without ART exposure appeared after approxi-
mately 2 months of anti-TB treatment (Figure 1).
In multivariate analysis (Table 5), ART exposure at any time
during TB treatment remained independently protective against
death(adjustedhazard ratio [HR]0.41,95%CI0.28–0.60).Beinga
male and having pulmonary TB were also independently associated
with a greater risk of death, and there was a trend towards greater
risk of death in those with prior anti-TB treatment.
Limiting the multivariate analysis to those patients who started
ART during TB treatment ( i.e. excluding the 133 who were
already on ART at the time of TB diagnosis) did not substantially
change the association between ART exposure and lower risk of
death (HR 0.32, 95% CI 0.20–0.52), nor did limiting the analysis
to males or females alone (HR 0.47, 95% CI 0.32–0.71 and HR
0.23, 95% CI 0.08–0.64).
Discussion
This evaluation provides the first evidence from India regarding
the operational challenges of delivering WHO-recommended
mortality-reducing TB-HIV interventions under general field
conditions. It also provides information on the daunting problem
of the high mortality of HIV-infected TB patients. In this resource-
limited setting, nearly 1 in 5 HIV-infected individuals diagnosed
with TB died during TB treatment. While previous studies have
reported high mortality among HIV-infected persons with
tuberculosis [17,18,23], the high death rate we observed in
Andhra Pradesh was particularly concerning given the provision of
free CPT and reasonable levels of ART uptake. These findings
imply that very high levels of ART uptake may be required to
substantively reduce tuberculosis case fatality rates.
With no additional resources or efforts beyond provider
trainings and monitoring by regular HIV and TB programme
staff, more than 95% of all detected HIV-infected TB patients
were initiated on CPT. Mixed adherence may have reduced the
effectiveness of CPT in this population, as just half of patients
collected .60% of their cotrimoxazole. With increased awareness
of CPT, adherence may improve; additional measures the
programmes should consider include use of peer-counselor
networks and non-governmental organizations to support and
encourage patients and providers.
We found that patients provided ART during TB treatment had
less than half the risk of death as those not provided ART. This
finding was independent of sex or previous TB treatment history,
and is consistent with findings from several other settings
[17,18,24,25]. This evidence from India strongly reinforces the
interpretation that ART is the single most potent intervention
available for public health programmes to reduce death during TB
treatment among HIV-infected individuals. Regardless of CPT
availability, in this setting the linkages to ART were arguably
inefficient. Of the 600 HIV-infected TB patients not already on
ART, despite evidence of referral, only 229 (38%) started ART
during TB treatment. Even when we included patients already on
ART before TB treatment, in total only 50% of TB patients
received any ART during TB treatment. While all of the
remaining patients may not have been immediately eligible for
ART, given the strong protection against death during TB
treatment, the TB and HIV programmes must urgently seek
improvements in ART referral efficiency and treatment uptake.
Table 2. CPT initiation delay and adherence among HIV-
infected TB patients, Andhra Pradesh 2007 (N=734).
Characteristic Sub-category N (%)
Cumulative
N( % )
Delay of initiation of
CPT, relative to date
of TB treatment
initiation
0 days (Before or on
the same day)
203 (27.6) 203 (27.6)
1–7 days 120 (16.4) 323 (44.0)
8–30 days 131 (17.9) 454 (61.9)
30–60 days 48 (6.5) 502 (68.4)
61–120 days 16 (2.2) 518 (70.6)
CPT started from
ART center
22 (3.0) 540 (73.6)





81–100% 214 (29.2) 214 (29.2)
61–80% 137 (18.6) 351 (47.8)
41–60% 88 (12.0) 439 (59.8)
21–40% 109 (14.9) 548 (74.5)
0–20% 111 (15.1) 659 (89.7)
Not available 75 (10.2) 734 (100)
*Relative to total duration of TB treatment taken during the evaluation period.
Abbreviations: CPT–cotrimoxazole prophylactic treatment; TB–tuberculosis; ART–
antiretroviral treatment.
doi:10.1371/journal.pone.0005999.t002
Table 3. Tuberculosis treatment outcomes among HIV-infected TB patients, Andhra Pradesh 2007 (N=734).
Treatment outcome NSP (%) NSN (%) NEP (%) Re-treatment (%) Total (%)
Treatment success 201 (72.4) 136 (71.6) 149 (88.7) 50 (50.5) 536 (73.0)
Default 12(4.3) 20 (10.5) 7 (4.2) 16 (16.2) 55 (7.5)
Failure 9(3.3) 1 (0.5) 0 3 (3.0) 13 (1.8)
Died 55 (19.9) 33 (17.4) 12 (7.2) 30 (30.3) 130 (17.7)
Total 277 (100) 190 (100) 168 (100) 99 (100) 734 (100)
Abbreviations: NSP–new pulmonary tuberculosis with sputum smears positive for acid-fast bacilli; NSN–new pulmonary tuberculosis with sputum smears negative for
acid-fast bacilli; NEP–New extrapulmonary tuberculosis.
doi:10.1371/journal.pone.0005999.t003
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females; the reasons for this finding are unclear. Overall case-
fatality rates among males with tuberculosis in India are modestly
higher than in females, and postulated reasons for higher mortality
among males include differences in treatment adherence, age
distribution, smoking behavior, and comorbidities [26,27,28].
Regardless, ART was associated with similar protection from
mortality in males and females alike. The 104 patients registered
as retreatment cases suffered from poor treatment success (50%)
and high case-fatality (30%). No information was available
regarding patient co-morbidities or drug resistance, but the very
high death rates among previously-treated patients urgently
warrants further exploration.
Limitations
Our evaluation was subject to several important limitations.
This was a retrospective evaluation of a demonstration conducted
under routine programme conditions; available information was
limited to that recorded on standard patient records which had
been modified to include additional HIV-related information.
With ascertainment of HIV-infection among TB patients based on
selective referral of those persons with HIV risk factors, the
patients identified might not be representative of the larger
population of HIV-infected TB patients. All 3 districts practiced
the same selective referral policy, but in Vizianagaram district a
simultaneous population-based survey of HIV infection among TB
patients provides insight into the effectiveness of the ascertainment
of HIV infection [29]. In Vizianagaram, the survey estimated a
6.5% (95% CI 4.5–9.4%) prevalence of HIV infection in TB
patients, which would imply that there were approximately 116
(81–168) HIV-infected TB patients among the cohort of 1788
registered from Vizianagaram in this study period. This evaluation
documented 95 HIV-infected TB patients from Vizianagaram, or
82% of the expected number, suggesting that the ascertainment as
sufficiently efficient to expect that these results could be
generalized to all HIV-infected TB patients in these districts.
Table 4. Bivariate analysis of risk factors for mortality during TB treatment among HIV-infected TB patients, Andhra Pradesh 2007
(N=734).
Characteristic Sub-Category Total Died, N (%) RR (95% CI)
District of Residence Ananthapur 322 56 (17.4) Referent
Vishakapatnam 317 60 (18.9) 1.09 (0.78–1.51)
Vizianagaram 95 14 (14.7) 0.85 (0.49–1.45)
Sex Male 493 102 Referent
Female 220 25 (11.4) 0.55 (0.37–0.83)
Not available 21 3 (14.9) 0.69 (0.24–2.00)
Previous TB treatment No 635 100 (15.8) Referent
Yes 99 30 (30.3) 1.92 (1.36–2.73)
Type of TB Pulmonary 551 113 (20.5) Referent
Extrapulmonary 183 17 (9.3) 0.45 (0.28–0.73)
Tuberculosis Classification New Smear-Positive 277 55 (19.9) Referent
New Smear-Negative 190 33 (17.4) 0.87 (0.59–1.29)
New Extrapulmonary 168 12 (7.1) 0.36 (0.20–0.65)
Re-Treatment (all types) 99 30 (30.3) 1.53 (1.04–2.23)
Age Group ,15 years 1 0
15–24 years 50 5 0.59 (0.25–1.04)
25–34 years 318 54 Referent
35–44 years 251 46 1.08 (0.76–1.54)
45–54 years 84 17 1.19 (0.73–1.94)
.55 years 27 8 1.74 (0.93–3.28)
Data not available 3 0
Delayed CPT initiation ,1 week 323 58 (18.0) Referent
1 week–2 months 179 30 (16.7) 0.93 (0.62–1.39)
.2 months 16 1 (6.3) 0.35 (0.05–2.4)
Data not available 194 36 (18.6) 1.03 (0.71–1.51)
CPT adherence .80% 214 39 (18.2) Referent
60–80% 137 30 (21.9) 1.20 (0.79–1.84)
40–60% 88 13 (14.8) 0.81 (0.46–1.44)
,40% 220 28 (12.7) 0.70 (0.45–1.09)
Data not available 75 20 (26.7) 1.46 (0.91–2.34)
ART during TB treatment No 354 87 (24.6) Referent
Yes 380 43 (11.3) 0.46 (0.33–0.64)
doi:10.1371/journal.pone.0005999.t004
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were not independently validated. Information about other
biomedical risk factors for death that may have confounded this
evaluation, such as severity of TB disease, drug resistance, severity
of immune suppression, or comorbidities, were not available. No
‘control’ areas without CPT were assessed because we did not seek
to evaluate the efficacy of CPT as an intervention, and
observational analysis of the association of CPT and mortality
were not possible since almost all patients were exposed to CPT
during TB treatment. The efficacy of CPT, however, has been
amply demonstrated in multiple settings. The recording of ART
information was dependent on feedback from the ART centre.
Some patients may not have had ART consumption recorded on
their TB treatment card, so we may have misclassified these
patients as not provided ART, and thus underestimated the
protective effect of ART in this population. We were also unable
to collect adequate information about sub-type of extrapulmonary
TB, patient CD4 count, or the specific timing of ART initiation.
Future studies should seek to collect this information to better
understand the finding of lower overall mortality in extrapulmo-
nary TB, and the protective effect of ART against mortality during
TB treatment.
Translating findings into policy and practice
On the basis of this experience, decentralized CPT delivery for
HIV-infected TB patients has been included in national TB-HIV
policies, and is being presently implemented in high HIV-
prevalence settings throughout India [30]. Joint TB-HIV trainings
now strongly emphasize the referral of HIV-infected TB patients
to ART centres. TB patient records and RNTCP registers have
been modified to include information on HIV status, CPT, and
ART. These recording enhancements will allow for routine
programme monitoring and supervision of the local programme
efficiency in detecting HIV-infection among TB patients and
linking these patients to CPT and ART. Operational research is
ongoing in other districts in India to understand weaknesses in
referral to ART centres and ART uptake.
Table 5. Multivariate analysis of risk factors for mortality







Antiretroviral treatment during TB
treatment
0.41 0.28–0.60
Male sex 1.67 1.07–2.62
Previous tuberculosis treatment 1.44 0.93–2.23
Pulmonary tuberculosis 1.89 1.11–3.21
Age Group
15–24 years 0.75 0.30–1.90
25–34 years Referent
35–44 years 0.89 0.61–1.34
45–54 years 1.12 0.68–2.00
.55 years 1.98 0.94–4.19
doi:10.1371/journal.pone.0005999.t005
Figure 1. Kaplan-Meier survival curve for HIV-infected TB patients, by exposure to antiretroviral treatment. ART=antiretroviral
treatment, TB=tuberculosis.
doi:10.1371/journal.pone.0005999.g001
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Cotrimoxazole prophylaxis can be delivered to HIV-infected
TB patients under programmatic conditions in India. Despite the
availability of free cotrimoxazole locally and ART from referral
centres, death was common and was strongly associated with the
absence of ART during TB treatment. These findings have been
translated into national policy and programme implementation
through the expansion of cotrimoxazole availability and training
on the importance of ART. To minimize death, the TB and HIV
programmes should target high levels of ART uptake and closely
monitor progress in implementation.
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